Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 7377

1.

Trichuris suis ova therapy in inflammatory bowel disease: A meta-analysis.

Huang X, Zeng LR, Chen FS, Zhu JP, Zhu MH.

Medicine (Baltimore). 2018 Aug;97(34):e12087. doi: 10.1097/MD.0000000000012087. Review.

2.

Low dose of azathioprine is effective to induce and maintain remission in active Crohn disease: A prospective observational study.

Qian X, Wang T, Shen J, Ran Z.

Medicine (Baltimore). 2018 Aug;97(34):e11814. doi: 10.1097/MD.0000000000011814.

3.

Interdisciplinary Updates in Crohn's Disease Reporting Nomenclature, and Cross-Sectional Disease Monitoring.

Baker ME, Fletcher JG, Al-Hawary M, Bruining D.

Radiol Clin North Am. 2018 Sep;56(5):691-707. doi: 10.1016/j.rcl.2018.04.010. Review.

PMID:
30119768
4.

Diagnostic utility of serological biomarkers in patients with Crohn's disease: A case-control study.

Yao F, Fan Y, Lv B, Ji C, Xu L.

Medicine (Baltimore). 2018 Aug;97(32):e11772. doi: 10.1097/MD.0000000000011772.

5.

Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails.

Li H, Shi FH, Huang SY, Zhang SG, Gu ZC, Wei JF.

Medicine (Baltimore). 2018 Jul;97(28):e11507. doi: 10.1097/MD.0000000000011507. Review.

6.

PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.

Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S.

Expert Opin Investig Drugs. 2018 Jul;27(7):623-629. doi: 10.1080/13543784.2018.1494722. Epub 2018 Jul 16. Review.

PMID:
29985060
7.

Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.

Ma C, Ascoytia C, McCarrier KP, Martin M, Feagan BG, Jairath V.

Dig Dis Sci. 2018 Oct;63(10):2555-2563. doi: 10.1007/s10620-018-5181-6. Epub 2018 Jun 29.

PMID:
29959726
8.

Cutaneous manifestations of metastatic Crohn's disease.

Schneider SL, Foster K, Patel D, Shwayder T.

Pediatr Dermatol. 2018 Sep;35(5):566-574. doi: 10.1111/pde.13565. Epub 2018 Jun 28. Review.

PMID:
29952016
9.

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.

D'Amico F, Fiorino G, Furfaro F, Allocca M, Danese S.

Expert Opin Investig Drugs. 2018 Jul;27(7):595-599. doi: 10.1080/13543784.2018.1492547. Epub 2018 Jul 6. Review.

PMID:
29938545
10.

Dermatologic manifestations of inflammatory bowel disease: a review.

Keyal U, Liu Y, Bhatta AK.

Discov Med. 2018 May;25(139):225-233. Review.

11.

Relationship between MRI quantified small bowel motility and abdominal symptoms in Crohn's disease patients-a validation study.

Gollifer RM, Menys A, Makanyanga J, Puylaert CA, Vos FM, Stoker J, Atkinson D, Taylor SA.

Br J Radiol. 2018 Sep;91(1089):20170914. doi: 10.1259/bjr.20170914. Epub 2018 Jun 19.

PMID:
29888980
12.

The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.

Lopetuso LR, Napoli M, Rizzatti G, Gasbarrini A.

Expert Opin Investig Drugs. 2018 Jun;27(6):543-551. doi: 10.1080/13543784.2018.1483333. Epub 2018 Jun 12. Review.

PMID:
29865875
13.

Children with Crohn's Disease Frequently Consume Select Food Additives.

Lee D, Swan CK, Suskind D, Wahbeh G, Vanamala J, Baldassano RN, Leonard MB, Lampe JW.

Dig Dis Sci. 2018 Oct;63(10):2722-2728. doi: 10.1007/s10620-018-5145-x. Epub 2018 Jun 4.

PMID:
29862484
14.

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C.

Gastroenterology. 2018 Sep;155(3):687-695.e10. doi: 10.1053/j.gastro.2018.05.039. Epub 2018 May 30.

PMID:
29857091
15.

Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases.

Clerc F, Novokmet M, Dotz V, Reiding KR, de Haan N, Kammeijer GSM, Dalebout H, Bladergroen MR, Vukovic F, Rapp E; IBD-BIOM Consortium, Targan SR, Barron G, Manetti N, Latiano A, McGovern DPB, Annese V, Lauc G, Wuhrer M.

Gastroenterology. 2018 Sep;155(3):829-843. doi: 10.1053/j.gastro.2018.05.030. Epub 2018 May 21.

PMID:
29792883
16.

Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn's Disease.

VanDussen KL, Stojmirović A, Li K, Liu TC, Kimes PK, Muegge BD, Simpson KF, Ciorba MA, Perrigoue JG, Friedman JR, Towne JE, Head RD, Stappenbeck TS.

Gastroenterology. 2018 Sep;155(3):815-828. doi: 10.1053/j.gastro.2018.05.028. Epub 2018 May 18.

PMID:
29782846
17.

Disease Activity Patterns Recorded Using a Mobile Monitoring System Are Associated with Clinical Outcomes of Patients with Crohn's Disease.

Kim ES, Kim SK, Jang BI, Kim KO, Kim EY, Lee YJ, Lee HS, Kwak SG; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD).

Dig Dis Sci. 2018 Sep;63(9):2220-2230. doi: 10.1007/s10620-018-5110-8. Epub 2018 May 19.

PMID:
29779084
18.

Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis.

Parisinos CA, Serghiou S, Katsoulis M, George MJ, Patel RS, Hemingway H, Hingorani AD.

Gastroenterology. 2018 Aug;155(2):303-306.e2. doi: 10.1053/j.gastro.2018.05.022. Epub 2018 Jul 5.

19.

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.

Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, Nguyen TM, Colombel JF.

Cochrane Database Syst Rev. 2018 May 12;5:CD012540. doi: 10.1002/14651858.CD012540.pub2. Review.

PMID:
29756637
20.

Endoscopic management of Crohn's strictures.

Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G.

World J Gastroenterol. 2018 May 7;24(17):1859-1867. doi: 10.3748/wjg.v24.i17.1859. Review.

Supplemental Content

Loading ...
Support Center